Resisting arrest: A switch from angiogenesis to vasculogenesis in recurrent malignant gliomas

Journal of Clinical Investigation

Volumn 120, Issue 3, 2010, Pages 663-667

  Greenfield, Jeffrey P ^a   Cobb, William S ^a   Lyden, David ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CD11 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GELATINASE B; SMAD4 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BONE MARROW CELL; BRAIN TUMOR; CELL PROLIFERATION; ENDOTHELIUM CELL; FIBROSARCOMA; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKULL IRRADIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR RECURRENCE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD11B; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MICE, NUDE; MONOCYTES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4; TRANSPLANTATION, HETEROLOGOUS; WHOLE-BODY IRRADIATION;

EID: 77949715989     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42345     Document Type: Note

References (25)

1. Kioi M, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010; 120(3):694-705.
2. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery. 2008;62(1):31-50; discussion 50-52.
3. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics. 2009; 6(3):447-457.
4. Jain RK, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610-622.
5. Gothert JR, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004; 104(6):1769-1777.
6. Lyden D, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194-1201.
7. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
8. Hwang SY, et al. Ionizing radiation induces astrocyte gliosis through microglia activation. Neurobiol Dis. 2006;21(3):457-467.
9. Wilson CM, Gaber MW, Sabek OM, Zawaski JA, Merchant TE. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys. 2009;74(3):934-941.
10. Levental KR, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891-906.
11. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13(3):193-205.
12. Garcia-Barros M, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155-1159.
13. Becher OJ, et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res. 2008;68(7):2241-2249.
14. Almand B, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678-689.
15. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol. 1999;21(4):241-252.
16. Rafat N, Beck G, Schulte J, Tuettenberg J, Vajkoczy P. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg. 2010;112(1):43-49.
17. Greenfield JP, et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery. 2009;64(5):819-826; discussion 826-827.
18. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8):911-920.
19. Yang L, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6(4):409-421.
20. Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 2007;67(18):8429-8432.
21. Zeitlin BD, Ellis LM, Nor JE. Inhibition of vascular endothelial growth factor receptor-1/wnt/{beta}-catenin crosstalk leads to tumor cell death. Clin Cancer Res. 2009;15(24):7453-7455.
22. Norden AD, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
23. Yung WK, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588-593.
24. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152-1160.
25. Greenfield JP, et al. Use of human neural tissue for the generation of progenitors. Neurosurgery. 2008;62(1):21-37; discussion 27-30.